# Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Source: https://onco.cc/trials/nct06191263/  
OnCo record `nct06191263` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Venetoclax in acute myeloid leukaemia, run by Ryvu Therapeutics SA, now recruiting.

## Summary

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML is a phase 2 interventional study registered as NCT06191263 by Ryvu Therapeutics SA, with 98 participants planned, started 2024-01-05 and due to reach its primary completion in 2027-08. Interventions recorded: RVU120 and Venetoclax.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06191263
- Phase: 2
- Setting: A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of RVU120 in Combination With Venetoclax in Participants With Acute Myeloid Leukemia Who Failed Prior Therapy With Ventoclax and a Hypomethylating Agent
- Sponsor: Ryvu Therapeutics SA
- Enrolled: 98

## Sources

- ClinicalTrials.gov NCT06191263: https://clinicaltrials.gov/study/NCT06191263

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [RVU120](https://onco.cc/drugs/rvu120/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [Ryvu Therapeutics](https://onco.cc/companies/ryvu-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06191263.json